Please provide your email address to receive an email when new articles are posted on . Adjuvant chemotherapy with modified FOLFIRINOX resulted in significantly longer survival vs. gemcitabine among ...

Please provide your email address to receive an email when new articles are posted on . Patients who received the neoadjuvant regimen had similar median OS as those who received upfront surgery and ...

STOCKHOLM, June 8, 2021 /PRNewswire/ -- Cantargia AB today announce that the clinical trial application to investigate the antibody nadunolimab (CAN04) in combination with the FOLFIRINOX chemotherapy ...

The chemotherapy regimen known as FOLFIRINOX produces an "impressive clinical response" in locally advanced pancreatic ductal adenocarcinoma, according to the authors of a new small, retrospective, ...

Compared with gemcitabine, a modified FOLFIRINOX regimen improved survival rates over five years of follow-up for patients with pancreatic ductal adenocarcinoma who underwent resection, although all ...

However Most Surveyed MCO Pharmacy Directors Consider Gemcitabine Plus Erlotinib To Be the Most Efficacious Treatment for Advanced Pancreatic Cancer, According to Findings from Decision Resources ...

"Remarkable" results with a new adjuvant chemotherapy regimen in patients with earlier stage pancreatic cancer have already changed clinical practice, experts report. After surgery, patients who ...

MELBOURNE, Australia, May 29, 2023 /PRNewswire/ -- Amplia Therapeutics Limited (ASX: ATX) ("Amplia" or the "Company") is pleased to announce new data showing the efficacy of its investigational FAK ...

FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study—Prodige 14 – ACCORD 21 (METHEP-2 ...

In the phase III ACCORD 11 trial, FOLFIRINOX was associated with the longest survival ever reported for patients with metastatic pancreatic cancer (11.1 months). However, toxicities associated with ...

Phase I randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib as first-line treatment in patients with metastatic pancreatic cancer (SWOG-0727).

Biliary tract cancers, including intrahepatic, perihilar, and extrahepatic cholangiocarcinoma and gallbladder cancer, are among the most aggressive gastrointestinal malignancies. Treatment options ...